Lupus erythematosus: Considerations for dentistry

Journal of the American Dental Association

Volumn 129, Issue 3, 1998, Pages 330-339

  De Rossi, Scott S ^a   Glick, Michael ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADRENAL INSUFFICIENCY; BACTERIAL INFECTION; BLEEDING; DENTAL CARE; ENDOCARDITIS; HEMATOLOGIC DISEASE; HUMAN; MOUTH DISEASE; PATHOPHYSIOLOGY; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VALVULAR HEART DISEASE;

ADRENAL INSUFFICIENCY; BACTERIAL INFECTIONS; DENTAL CARE FOR CHRONICALLY ILL; ENDOCARDITIS; GLUCOCORTICOIDS; HEART VALVE DISEASES; HEMATOLOGIC DISEASES; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOUTH DISEASES; SKIN DISEASES;

EID: 0032011861     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.1998.0207     Document Type: Article

References (54)

1. Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. Ann Rev Immunol 1993;11:79-104.
2. Hess EV, Mongey AB. Drug-related lupus. Bull Rheum Dis 1991;40:1-8.
3. Callen JP. Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 1994;12:201-6.
4. Peacock DJ, Cooper C. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1995;7:82-6.
5. Petri M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:395-401.
6. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-70.
7. Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:402-8.
8. Abu-Shakra M, Urowitz MB, Gladman DD. Improved survival in a cohort of SLE patients compared to the general population over a 25-year period of observation. Arthritis Rheum 1994;37(Supplement 9):S216.
9. Hellman DB. Arthritis and musculoskeletal disorders. In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current medical diagnosis and treatment. Stamford, Conn.: Appleton & Lange; 1996:719-67.
10. Fessier BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus: diagnosis and management. Rheum Dis Clin North Am 1995;21(1):81-98.
11. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996;101:100-7.
12. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts - Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995;122:940-50.
13. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
14. Bluestein HG. The central nervous system in systemic lupus erythematosus. In: Lahita RD, ed. Systemic lupus erythematosus. New York: Churchill Livingstone; 1992:639-55.
15. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994;20:129-58.
16. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients and prevention practices. Medicine (Baltimore) 1992;71:291-302.
17. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996;335:1424-30.
18. Jonnson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-50.
19. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988;319:817-23.
20. Luce EB, Montgomery MT, Redding SW. The prevalence of cardiac valvular pathosis in patients with systemic lupus erythematosus. Oral Surg Oral Med Oral Pathol 1990;70:590-2.
21. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701-37.
22. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus. Circulation 1990;82:369-75.
23. Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988;85:645-50.
24. Asheron RA, Cervera R. Antiphospholipid syndrome. J Invest Dermatol 1993;100:21S-7S.
25. Rhodus NL, Johnson DK. The prevalence of oral manifestations of systemic lupus erythematosus. Quintessence Int 1990;21:461-4.
26. Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA. Sjögren's syndrome in systemic lupus erythematosus. J Rheumatol 1990;17:201-4.
27. Cronin ME. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:99-116.
28. Esdaile JM, Danoff D, Rosenthall L, Gutkowski A. Deforming arthritis in systemic lupus erythematosus. Ann Rheumatol Dis 1981;40:124-6.
29. Hochberg MC, Petri M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1993;5:575-86.
30. De Rossi SS, Glick M. Dental considerations for the patient with renal disease receiving hemodialysis. JADA 1996;127:211-9.
31. Bernstein JM, Stanley DE. Choice of antibiotics, pharmacokinetics, and dose adjustments in acute and chronic renal failure. Med Clin North Am 1990;4:1059-73.
32. Roura M, Lopez-Gil F, Umbert P. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica 1991;182(1):56-8.
33. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992;326:226-30.
34. Glick M. Glucocorticosteroid replacement therapy: a literature review and suggested replacement therapy. Oral Surg Oral Med Oral Pathol 1989;67:614-20.
35. Little JW, Falace DA, Miller CS, Rhodus NL. Dental management of the medically compromised patient. 5th ed. St. Louis: Mosby;1997.
36. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.
37. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579-87.
38. Joffe II, Jacobs LE, Owen AN, Ioli A, Kotler MN. Noninfective valvular masses: review of the literature with emphasis on imaging techniques and management. Am Heart J 1996;131:1175-83.
39. Lehman TJA, Palmeri ST, Hastings C, Klippel JH, Plotz PH. Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol 1983;10:655-8.
40. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997;264:1794-801.
41. Herman WW, Konzelman JL, Sutley SH. Current perspectives on dental patients receiving coumarin anticoagulant therapy. JADA 1997;128:327-35.
42. Herman WW, Konzelman JL. Angina: an update for dentistry. JADA 1996;127:98-104.
43. Freymiller EG, Aghaloo T. Dental management of patients with coronary artery disease. CDA J 1995;23:41-6.
44. Beutler E. Platelet transfusions: the 20,000/mL trigger. Blood 1993;81:1411-3.
45. De Rossi SS, Glick M. Bleeding time: an unreliable predictor of clinical hemostasis. J Oral Maxillofac Surg 1996;54:1119-20.
46. De Rossi SS, Glick M. Dental considerations in asplenic patients. JADA 1996;127;1359-63.
47. Sindet-Petersen S. Haemostasis in oral surgery. Dan Med Bull 1991;38(6):427-43.
48. Cohen SG, Glick M. Dental correlations: platelet and vascular disorders. In: Rose LF, Kaye D, eds. Internal medicine for dentistry. 2nd ed. St. Louis: Mosby; 1990:369-71.
49. National Institutes of Health. Consensus Development Conference on Oral Complications of Cancer Therapies: diagnosis, prevention, and treatment. JADA 1989;119:179-83.
50. Miranda C, Lozada-Nur F. Oral hairy leukoplakia in an HIV-negative patient with systemic lupus erythematosus. Compend Contin Educ Dent 1996;17(4):408-12.
51. Karjalainen TK, Tomich CE. A histopathologic study of oral mucosal lupus erythematosus. Oral Surg Oral Med Oral Pathol 1989;67:547-54.
52. Brown RS, Flaitz CM, Hays GL, Trejo PM. The diagnosis and treatment of discoid lupus erythematosus with oral manifestations only: a case report. Compend Contin Educ Dent 1995;15(6):724-34.
53. Symons AL, Symons DJ. Pulpal obliteration related to long-term glucocorticosteroid medication. Spec Care Dentist 1994;14(3):103-7.
54. Bade DM, Lovasko JH, Montana J, Waide FL. Acute closed lock in a patient with lupus erythematosus: a case review. J Craniomandib Disord Facial Oral Pain 1992;6:208-12.